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How do we raise the profile of  
tissue viability?
 
SP:   I have been involved in 
the development of tissue viability 
services for 16 years and have been 
reasonably successful in securing 
funding for new posts. However, this 
has only been achieved through local 
primary and secondary care services 
working together to identify problem 
areas and overcome any barriers that 
may prevent service development. 
The fragmentation of trusts is 
making collaboration even more 
difficult, and tissue viability is 
rarely prioritised over other more 
essential services until an ‘incident’ or 
complaint brings it to the attention of 
NHS managers. 
The recent national guidance does 
help and forces managers (some of 
whom have no medical experience) 
to find out more about tissue viability. 
However, what exactly it is that 
constitutes a tissue viability service is 
not always clear to the outsider. 
As the NHS changes and different 
specialties provide different services, 
tissue viability clinicians need to be 
clearer about the specialist skills 
that they bring to patient care. If 
necessary, this should involve a 
national strategy, which is clearly 
communicated with standardised 
service specifications and improved 
quality measures. 
Some areas of tissue viability do 
have a high profile, for example From 
Good to Great (DH, 2009) raises the 
issue of preventable pressure ulcers 
The NHS quality agenda has been 
discussed, debated, explored and 
highlighted over the past year in an 
effort to meet the challenges laid down 
by the Department of Health (DH). 
The terms quality accounts, innovation, 
productivity and prevention (QIPP), 
and the Commissioning for Quality 
and Innovation (CQUIN) payment 
framework should by now be familiar to 
most clinicians. 
The CQUIN framework aims to place 
quality improvement and innovation 
at the heart of negotiations between 
commissioners and providers to ensure 
that local quality improvement priorities 
are discussed at board level. The CQUIN 
payment framework also stipulates 
that a proportion of the income paid 
to healthcare providers is conditional 
on quality and innovation. This will help 
to create an NHS where quality is the 
organising principle, as set out in High 
Quality Care for All (DH, 2008). 
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There are in excess of 200 new indicators 
that make it essential for tissue viability 
clinicians to benchmark their work against 
that of their peers. Each strategic health 
authority (SHA) has identified quality 
initiative schemes and indicators based 
around four sectors — acute, community, 
mental health and ambulance services. 
The Chief Nursing Officer for England has 
produced eight high impact action themes 
for nursing and midwifery, including: ‘Your 
skin matters: no avoidable pressure ulcers 
in NHS-provided care.’ 
Additionally, the Leg Club social model, 
which has been designed for use in 
patients with leg ulcers, has been 
identified by the DH as an area of good 
practice for its approach to quality care. 
The DH document NHS 2010–2015. From 
Good to Great (DH, 2009) clearly states 
that there will be ‘safer care for patients, 
who can be confident that they will be 
protected from avoidable harm’. It highlights 
pressure ulcers as an area that needs to be 
addressed and insists that the tariff payment 
system will not reward poor quality or 
unsafe care. Penalties can be applied to 
those areas that do not meet quality or 
patient satisfaction outcomes, and there is 
an expectation that over time up to 10% 
of trusts’ income could be dependent on 
patient experience and satisfaction.
However, tissue viability is not always 
recognised as a speciality and clinicians 
need to ensure that it is seen as a 
discipline that impacts on other areas, 
such as nutrition, pain management, 
infection and medicines management. 
In the future NHS, quality is going to be 
paramount, but what support will tissue 
viability practitioners receive in meeting 
these targets and indicators?              KO
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and methicillin-resistant Staphylococcus 
aureus (MRSA) infections in a section 
entitled ‘safer care’. As such conditions 
can be fatal and the compensation 
risks to trusts are high, these areas 
often receive a lot of attention from 
managers. However, many other 
wound types are also seriously 
debilitating and this is why the 
speciality as a whole needs to develop 
a unique voice.    
SB:   The profile of tissue viability 
services in the NHS can be raised 
by demonstrating the value of these 
services and the contribution they 
can make to patient care. There are 
various ways to do this, for example:
8 Demonstrating a reduction in 
patient risk through reporting 
prevalence and incidence data to 
trust boards (infection control 
teams do this regularly)
8 Demonstrating an improvement 
in  patients’ experiences through 
reporting different patient cases 
and their outcomes to trust 
boards
8 Compiling annual reports that 
clearly define the numbers of 
patients treated, the costs of 
equipment and a breakdown of 
prevalence/incidence data to  
trust boards.
RS:   It is imperative that tissue 
viability aligns itself to the national 
quality agenda. Tissue viability leads 
around the country need to continue 
to engage with key NHS stakeholders 
in order to raise the awareness of 
their speciality. Endorsement needs to 
be sought from the highest level and 
evidence provided as to the quality of 
local tissue viability services. 
Engaging directly with the relevant 
people in the DH should be part of 
a project plan that aims to raise the 
awareness of tissue viability services. 
Importantly, the correct language 
and terminology needs to be used 
when attempting to engage with 
non-clinical colleagues in the NHS. 
Hard facts and figures are needed to 
express precisely how tissue viability 
can align itself to the three main 
domains of the quality agenda — 
patient safety, clinical effectiveness and 
patient satisfaction. 
What support do nurse directors offer 
to develop the indicators and raise the 
profile of tissue viability?
SP:   This depends upon the nurse 
director and how other targets can be 
linked to tissue viability. Initiatives such 
as Productive Wards and Essence 
of Care have both contributed to 
raising the profile of tissue viability 
in primary and secondary care, and 
have encouraged more staff, such as 
ward managers and tissue viability link 
nurses, to become active and involved. 
They also help services to prioritise 
delivery targets. 
 
However, it is an unfortunate truth 
that adverse events often demand 
the most attention, resulting in 
service reviews, policy development, 
education and further training. Extra 
resources that enable all of this 
to be put in place are not usually 
forthcoming unless cost savings have 
been made elsewhere. 
Our service has been involved 
in providing evidence for the 
NHS Litigation Authority (LA) risk 
management standards for primary 
care trusts and these are now being 
replaced by Quality Care Commission 
standards. Demonstrating these 
standards can make tissue viability 
services more robust and fit for 
purpose. 
However, all of this is only 
possible by having good links with 
governance teams and other specialist 
services, as well as the support of an 
administrative team. Also, if clinicians 
can produce examples of good 
service delivery, this may result in a 
trust director championing their tissue 
viability service and support will then 
follow naturally.  
SB:   The nurses in a tissue viability 
service should endeavour to report 
directly to the trust’s nurse director 
in order to build a sound working 
relationship. This will ensure that 
tissue viability issues are recognised 
and supported within the trust.
What are the societies doing to promote 
and develop this agenda?
SP:   The various societies need 
to work towards the common goal 
of establishing and promoting tissue 
viability as a specialty. There is a never-
ending list of projects that need to 
be pushed forward, however any 
new initiative should be part of an 
over-arching plan to establish a clear 
strategy for tissue viability. 
Working with colleagues in the 
British Dermatological Nurses Group 
(BDNG) demonstrated to me just 
how successful cohesion can be. 
RS: Tissue viability leads around the countr y need to continue to engage with key NHS stakeholders in 
order to raise the awareness of their speciality. Endorsement needs to be sought from the highest level.
SB: The nurses in a tissue viability service should endeavour to report directly to the trust’s nurse director in 
order to build a sound working relationship. This will ensure that tissue viability issues are supported.
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The BDNG is recognised as the 
main consulting body on national 
dermatology issues, represents the 
specialty in parliament, and runs its 
own conference which is integrated 
with that of the British Association of 
Dermatologists (BAD).    
SB:  The societies associated 
with tissue viability support and 
disseminate developments in practice 
and research, both through journal 
publications and at conferences and 
study days. They also develop and 
publicise measurement tools, for 
example, those that facilitate audit 
and prevalence data collection. These 
are all useful in demonstrating the 
value of tissue viability.
RS:   The specialty as a whole 
needs to ensure that any messages 
about the quality agenda are 
communicated clearly and 
consistently across all of the various 
tissue viability societies. Some groups 
have realised the importance of 
using their events to promote the 
quality agenda, for example at the 
next Leg Ulcer Forum conference, 
Gerry Bolger, Programme Director of 
Quality in Caring at the DH, has been 
invited as a guest speaker and will 
help to outline the quality agenda to 
everyday clinicians. 
When the indicators are in place how will 
they be measured and what penalties will 
occur should they not be met? 
SP:   It is difficult to predict what 
measurements will be acceptable in 
the future and if the current methods 
will continue, or whether each 
patient outcome will be monitored 
on a case-by-case basis and reported 
via a different mechanism, i.e. 
clinical incident reporting. This is a 
complicated area as not all of the 
pressure ulcer grades are classed as 
clinical incidents.
It would be interesting to know 
exactly who is advising the DH on 
this policy, as this is where tissue 
viability clinicians should have a 
level of influence. If a pressure ulcer 
represents a ‘never event’, it will have 
to be determined whether the event 
was considered preventable or not — 
but who is to decide this? 
Similarly, when investigations 
into an event are being completed, 
trying to determine whether or not 
it was preventable can be difficult, 
despite other practice-related issues, 
i.e. adequate documentation being 
flagged up.
SB:   Measuring patient outcomes 
is generally a positive move, which 
should enable services to develop 
and improve. Tissue viability is being 
recognised as an important aspect of 
patient care, which is what many of us 
have been advocating for a long time. 
However, it is important that 
the sanctions or penalties used to 
discourage inadequate care do not 
negatively impact on the reporting of 
tissue damage. 
The principles of clinical 
governance revolve around a ‘no 
blame’ culture and engendering an 
atmosphere of learning. Initiatives such 
as the Safer Patient Initiative (Institute 
for Healthcare Improvement [IHI] 
and the Health Foundation, 2004), 
1,000 Lives campaign (www.wales.
nhs.uk/sites3/home.cfm?orgid=781) 
and Transforming Care at the Bedside 
(TCAB) (Robert Wood Johnson 
Foundation and IHI, 2003) have been 
effective in improving clinical practice 
and patient outcomes. 
RS:   Although the Chief Executive 
of the NHS, Sir David Nicholson, 
has stated that all secondary care 
providers will have to publish quality 
accounts this year, there is still no 
real national consensus on what they 
should look like. Part of the difficulty 
is that there is no agreement on who 
will be accountable for the content. 
However, this should not be an 
excuse to be complacent or tentative.
These quality accounts are going 
to happen and we should see them 
as an opportunity not a threat. After 
all, they could raise the awareness of 
tissue viability in the NHS.
It is important that tissue viability 
clinicians develop a small number 
of good quality metrics, rather than 
trying to measure a wide range  
of variables. 
The most obvious place to star t 
is with pressure ulcer management, 
which clearly falls under the remit of 
patient safety. The DH has suggested 
that grade 3 and 4 pressure ulcers 
will be identified as never events 
and penalties and incentives will be 
assigned accordingly. This provides 
clinicians with an opportunity 
to properly measure and report 
pressure ulcer prevention and 
management.  
SP: Commissioners want evidence of quality provision via patient feedback and experience and 
monitoring this will help tissue viability ser vices find a way forward. 
SB: Quite simply, if companies do not support tissue viability clinicians, then the entire specialty will suffer, 
including the commercial interests of industry.
Debate6(1) .indd   4 05/03/2010   17:03
153Wounds uk, 2010, Vol 6, No 1
When measuring quality, 
clinicians need to be looking for 
improvement, rather than just 
performing measurements as an 
end in themselves. Clear objectives 
need to be set and ideal outcomes 
identified before any measurements 
are conducted. Indicators and metrics 
are vital as they ensure that a service 
like tissue viability can demonstrate  
its quality.   
The DH identifies success in the 
national operating framework as 
having two main areas:
8 Providing more services closer to 
home with a reduction in activity 
and investment in the acute sector
8 An identifiable, clear quality of 
service across all standards and 
patient pathways.
One of the biggest opportunities 
for quality and productivity in tissue 
viability services is at the interface 
of primary and secondary services, 
where clinicians can ensure that care 
is seamless and always in the patient’s 
best interest.
Caring for vulnerable skin and prevention 
of ulcers is a basic element of care,  
yet the CQUIN did not identify this as a 
priority. Why do you think this was not 
recognised?
SP:   CQUIN is a general 
framework for commissioning quality 
and innovation, therefore no specific 
area is mentioned as we have to fit 
our ideas into a proposal that will 
be locally agreed. This means that 
once again tissue viability will be 
competing for priority against  
other services. 
It is also recommended that 
any area, such as the prevention 
of pressure ulcers, is measured by 
demonstrable patient outcome. The 
East Midlands has now produced 
its framework and pressure ulcers 
feature in the community sector, with 
the objective: ‘To measure, monitor 
and reduce the incidence of grade 2 
and higher pressure ulcers.’
Improving data collection and 
ensuring that standards of care are 
in place should fit with CQUINs 
aims as data collection is specifically 
mentioned as a way of reducing 
pressure ulcers – without good initial 
data, a reduction cannot be robustly 
demonstrated.  
Our trust collects incidence and 
prevalence data and has a reasonably 
low incidence of grade 3 and 4 
pressure ulcers, but it has always been 
a concern of mine that data collection 
methods are not standardised 
nationally. There is a clinical incident 
report and investigation for each 
full thickness ulcer that develops in 
our trust. This is an area we are still 
learning about in order to improve 
care and monitor the type of issues 
that arise. 
Commissioners want evidence of 
quality provision via patient feedback, 
and monitoring this will help tissue 
viability services find a way to 
improve quality in the future. 
 
The reward for achieving the 
CQUIN targets will be extra funding, 
but this is non-recurrent and 
paid gradually dependent on any 
improvements being quantified.  
SB:   As I work in Wales and we do 
not have this system, I feel unable to 
comment accurately. 
Does industry have a role to play in 
updating clinicians’ knowledge on national 
healthcare policy??
SP:   Educating clinicians 
is imperative, but often the 
interpretation placed on new 
guidance is seen as having a ‘hidden 
agenda’, especially if the information is 
provided by companies. 
However, if employers do not 
provide updates about new guidance 
and clinicians do not regularly attend 
conferences, it can be difficult for 
them to access information. Reading 
about guidelines does not always 
provide an accurate idea of how they 
should be implemented in practice. 
I think industry can help fill 
this void, especially if they recruit 
impartial and experienced speakers. 
However, even these can only provide 
an overview as interpretation at 
local level can be quite different. 
This is one area where clinicians 
can work together to develop ideas 
for proposals and secure funding to 
improve tissue viability practice.   
SB:   Yes, industry does have a 
role as it has a proven track record 
of providing and funding generic 
education, which is not product- or 
company-focused. 
Some companies have put on 
workshops and study days for TVNs 
on topics related to their role as a 
specialist, including how to deal with 
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organisational change in the NHS and 
leadership and management. Other 
companies provide generic education 
for nurses working in clinical practice 
in subjects such as pressure ulcer 
prevention, wound and patient 
assessment, documentation and 
patient evaluation. 
Industry can help by updating 
clinicians and inviting independent 
speakers to workshops and study 
days. A broad range of presentations 
of educational materials are available, 
from group teaching and workshops 
through to web-based materials and 
programmes.
Those managing clinicians’ 
education should liaise with those 
companies that provide unbiased 
education, as well as using the 
materials provided by the associations. 
This will provide a balanced approach 
to education. 
RS:   Yes, industry does have a 
role to play here, but importantly the 
rationale for offering education must 
be clearly identified to refute any 
suspicion of commercial bias. 
As cost is becoming such an 
important driver for clinical decision-
making in the NHS, it is imperative 
that tissue viability services provide 
evidence on the rationale and cost-
effectiveness of any advanced wound 
care products used. Moreover, 
industry can support clinicians by 
offering economic evidence on the 
value of products used.
In this current climate, where the 
need for productivity and efficiency 
savings are highlighted at every 
possible opportunity, accurately 
measuring and reporting quality 
in tissue viability services is more 
important than ever.
Who is the national voice of  
tissue viability?
SP:   I wish I could answer this 
question with a definitive answer 
because it is imperative that the 
specialty has a powerful voice. There 
are influential individuals in tissue 
viability, but the societies should 
be responding to policymakers on 
their members’ behalf. Due to the 
dissolution and merger of various 
societies, we have to refocus and 
work together to ensure a cohesive 
approach to raising the profile of  
the speciality. 
Established regional networks 
exist and these need to 
communicate via a national centre in 
order that tissue viability information 
is consistently disseminated. This 
kind of information sharing is vital, 
especially if the views of clinicians are 
to be sought.
SB:   Unfortunately, there is no one, 
national voice. Because of the UK’s 
political system the trend is towards 
devolvement, thereby health services 
can be fragmented across the various 
countries. 
But do we need one voice, or is 
the plethora of associations a positive 
thing, allowing for a diversity in focus 
and differing yet complementary 
ways of providing tissue viability 
information? I belong to several 
associations and each give me 
something different and useful. 
In return, I have been privileged 
to sit on some of the committees 
and contribute to the work the 
associations carry out. Having one 
single voice would, in my view, 
inhibit the growth of the specialty 
and engender a culture of infighting 
among the various tissue viability 
associations. 
  
RS:   At present there does not 
seem to be one national voice for 
tissue viability. In the future, tissue 
viability groups, societies and forums 
need to work together to offer clear, 
consistent messages on quality and 
other important national issues. A 
national communication platform 
also needs to be developed in 
order to disseminate messages and 
information.
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